Core Viewpoint - A significant block trade of 40,000 shares of Ailis occurred on August 20, with a transaction value of 2.8796 million yuan, reflecting a discount of 20.29% compared to the closing price of the day [1] Group 1: Block Trade Details - The block trade involved a transaction price of 71.99 yuan per share [1] - The buyer was Guohai Securities Co., Ltd. Sichuan Branch, while the seller was Changjiang Securities Co., Ltd. Wuhan Hanxi First Road Securities Branch [1] - In the last three months, Ailis has recorded a total of three block trades, amounting to 7.1361 million yuan [1] Group 2: Stock Performance - Ailis closed at 90.32 yuan on the day of the block trade, with a slight increase of 0.37% [1] - The daily turnover rate was 0.90%, with a total trading volume of 362 million yuan [1] - Over the past five days, the stock has seen a cumulative increase of 0.76%, with a net outflow of funds totaling 12.789 million yuan [1] Group 3: Margin Financing Data - The latest margin financing balance for Ailis is 834 million yuan, which has decreased by 20.7589 million yuan over the past five days, representing a decline of 2.43% [1]

Group 1 - A total of 8 stocks from the Sci-Tech Innovation Board (STAR Market) experienced block trading on August 20, with a cumulative transaction amount of 1.04 billion yuan and a total trading volume of 243.32 million shares [1][2] - The stock with the highest transaction amount was Changying Tong, with a trading volume of 1.22 million shares and a transaction amount of 60.34 million yuan. Other notable stocks included Canxin Technology and Funeng Technology, with transaction amounts of 19.01 million yuan and 8.48 million yuan, respectively [1][2] - All stocks involved in block trading were sold at a discount compared to their closing prices, with the highest discount rates seen in Ailis, Gaoling Information, and Borui Pharmaceutical, at 20.29%, 12.30%, and 9.09% respectively [1][2] Group 2 - In terms of capital flow, four stocks saw net inflows of funds, with Canxin Technology, Daotong Technology, and Borui Pharmaceutical leading with net inflows of 29.08 million yuan, 17.82 million yuan, and 5.44 million yuan, respectively. Conversely, Funeng Technology, Ailis, and Aiwei Technology experienced net outflows of 24.92 million yuan, 21.88 million yuan, and 3.79 million yuan [2] - The average increase for the stocks involved in block trading was 1.44%, with the highest increases recorded for Canxin Technology, Daotong Technology, and Changying Tong, at 7.59%, 1.86%, and 0.71% respectively [1][2]

Core Viewpoint - Shanghai Heyu Biopharmaceutical Technology Co., Ltd. announced the approval of its IND application for the oral PD-L1 inhibitor ABSK043 in combination with the KRAS G12C inhibitor, citric acid giredestrant, for treating KRAS G12C mutated non-small cell lung cancer (NSCLC) patients [1] Group 1 - The clinical study is an open-label Phase II trial assessing the safety, tolerability, and efficacy of ABSK043 combined with citric acid giredestrant in patients with locally advanced or metastatic NSCLC carrying KRAS G12C mutations [1] - The collaboration agreement between Heyu Biopharmaceutical and Ailis was established in March 2025 for the combined treatment of ABSK043 and citric acid giredestrant [1] - Previous disclosures indicated another collaboration exploring the combination of ABSK043 with Ailis's developed Vemurafenib for treating advanced NSCLC, with the first patient dosing expected to be completed by December 2024 [1] Group 2 - Updated Phase I study results show that ABSK043 as a monotherapy has demonstrated good safety and impressive anti-tumor activity, particularly in patients with high PD-L1 expression and those with EGFR or KRAS mutations [1]

Core Viewpoint - Shanghai Heyu Biopharmaceutical Technology Co., Ltd. announced the approval of its IND application for the oral PD-L1 inhibitor ABSK043 in combination with the KRAS G12C inhibitor, citric acid gorasetinib, for treating KRAS G12C mutated non-small cell lung cancer (NSCLC) patients [1] Group 1 - The IND application was approved by the Center for Drug Evaluation (CDE) of the National Medical Products Administration (NMPA) of China [1] - The study is an open-label Phase II clinical trial assessing the safety, tolerability, and efficacy of ABSK043 in combination with citric acid gorasetinib for patients with locally advanced or metastatic NSCLC carrying KRAS G12C mutations [1] - A previous collaboration between Heyu and Elysium was disclosed to explore the combination of ABSK043 with Elysium's developed drug, furmetinib, for treating advanced NSCLC, with the first patient dosing expected to be completed by December 2024 [1] Group 2 - Updated Phase I study results show that ABSK043 as a monotherapy has good safety and impressive anti-tumor activity, with higher response rates observed in patients with high PD-L1 expression and those with EGFR or KRAS mutations [1]

Core Viewpoint - The approval of the IND application for the oral PD-L1 inhibitor ABSK043 in combination with the KRAS G12C inhibitor from Shanghai Elysium Pharmaceutical Technology Co., Ltd. marks a significant advancement in the treatment of KRAS G12C mutated non-small cell lung cancer (NSCLC) patients [1] Group 1 - The IND application was approved by the Center for Drug Evaluation (CDE) of the National Medical Products Administration of China [1] - The collaboration agreement between the company and Elysium regarding the combined use of ABSK043 and citric acid gorasetinib tablets was reached in March 2025 [1] - The study is an open-label Phase II clinical trial assessing the safety, tolerability, and efficacy of ABSK043 in combination with citric acid gorasetinib tablets for patients with locally advanced or metastatic NSCLC carrying the KRAS G12C mutation [1]

Core Viewpoint - The approval of the IND application for the oral PD-L1 inhibitor ABSK043 in combination with the KRAS G12C inhibitor from Shanghai Elysium Pharmaceutical for treating KRAS G12C mutated non-small cell lung cancer (NSCLC) patients marks a significant advancement in cancer treatment [1] Group 1 - The IND application for the combination therapy has been approved by the Center for Drug Evaluation (CDE) of the National Medical Products Administration of China [1] - The collaboration agreement between the company and Elysium regarding the use of ABSK043 with the citric acid gorasetinib tablets is set to be effective from March 2025 [1] - The approved study is an open-label Phase II clinical trial assessing the safety, tolerability, and efficacy of ABSK043 in combination with citric acid gorasetinib for patients with locally advanced or metastatic NSCLC carrying KRAS G12C mutations [1]

香港交易及結算所有限公司及香港聯合交易所有限公司對本公告的內容概不負責，對其準確性 或完整性亦不發表任何聲明，並明確表示，概不就因本公告全部或任何部分內容所產生或因依 賴該等內容而引致的任何損失承擔任何責任。 Abbisko Cayman Limited 和譽開曼有限責任公司 （於開曼群島註冊成立的有限公司） （股份代號：2256） 自願性公告 和譽醫藥的口服PD-L1抑制劑ABSK043與艾力斯的 KRAS G12C抑制劑枸櫞酸戈來雷塞片聯合用藥治療NSCLC的 IND申請獲CDE批准 徐耀昌博士 主席 上海，2025年8月20日 於本公告日期，本公司董事會包括執行董事徐耀昌博士、喻紅平博士及嵇靖博 士；以及獨立非執行董事孫飄揚博士、孫洪斌先生及徐海音女士。 1 和譽醫藥的口服PD-L1抑制劑ABSK043與艾力斯的KRAS G12C抑制劑枸櫞 酸戈來雷塞片聯合用藥治療NSCLC的IND申請獲CDE批准 於2025年8月20日，上海和譽生物醫藥科技有限公司（「和譽醫藥」）宣佈，其在研 的口服PD-L1抑制劑ABSK043與上海艾力斯醫藥科技股份有限公司（「艾力斯」）的 KRAS G12C抑制劑枸櫞酸戈來雷塞 ...

8月20日，艾力斯大宗交易成交4万股，成交额287.96万元，占当日总成交额的0.79%，成交价71.99元，较市场收盘价90.32元折价20.29%。 | 2025-08-20 | 艾力斯 | 688578 | 71.99 | 287.96 | 国海证券股份有限 | 长江证券股份有限 | | --- | --- | --- | --- | --- | --- | --- | | 交易日期 | 证券简称 | 证券代码 | 成交价(元) 成交金额(万元) 成交量( * ) 买入营业部 | | 公司四川分公司 | 卖出营业部 公司武汉汉西一路 | ...

Group 1 - The Shanghai Stock Exchange Sci-Tech Innovation Board Biopharmaceutical Index decreased by 0.91% as of August 20, 2025, with mixed performance among constituent stocks [1] - Heartbeat Medical led the gains with an increase of 3.13%, while Yuandong Biological experienced the largest decline [1] - The market for the Sci-Tech Medical ETF managed by Harvest saw a turnover rate of 24.05% and a transaction volume of 62.637 million yuan, indicating active trading [3] Group 2 - The latest scale of the Sci-Tech Medical ETF reached 263 million yuan, marking a one-month high and ranking first among comparable funds [3] - The ETF has seen continuous net inflows over the past three days, with a maximum single-day net inflow of 6.157 million yuan, totaling 15.2382 million yuan [3] - The net value of the ETF increased by 56.59% over the past year, with the highest monthly return since inception being 23.29% [3] Group 3 - The total amount of business cooperation for innovative drugs in China is projected to reach 51.9 billion USD in 2024, with a record 1.25 billion USD upfront payment transaction between 3SBio and Pfizer in 2025 [4] - The Chinese innovative drug sector has seen a 25.02% increase year-to-date, ranking fourth among 31 industries, with a current PE ratio of 31.31 times [4] - The National Healthcare Security Administration has introduced a temporary management method for disease-based payment, promoting payment reform in the healthcare sector [4] Group 4 - As of July 31, 2025, the top ten weighted stocks in the Sci-Tech Innovation Board Biopharmaceutical Index accounted for 49.14% of the index, with leading companies including United Imaging and BeiGene [4][6] - The performance of individual stocks varied, with United Imaging down by 0.26% and BeiGene up by 0.95% [6] - Investors without stock accounts can access the Sci-Tech Medical ETF through the Harvest Sci-Tech Medical ETF linked fund [6]

Investment Rating - The investment rating for the company is "Accumulate" (maintained) [2] Core Views - The company is expected to achieve significant revenue growth, with projected revenues of 4.5 billion, 5.5 billion, and 6.1 billion RMB for the years 2025, 2026, and 2027 respectively, reflecting growth rates of 26.5%, 22.2%, and 10.9% [9] - The net profit is forecasted to reach 1.896 billion, 2.591 billion, and 3.033 billion RMB for the same years, with net profit growth rates of 32.6%, 36.7%, and 17.1% [9] - The company has made significant progress in clinical research, particularly with the drug Vomeletin, which has received breakthrough therapy designation for treating NSCLC [9] - The drug Goleirese has been successfully approved and is expected to enter the national medical insurance directory, which will accelerate its market penetration [9] Financial Performance and Forecast - Revenue for 2023 is reported at 2,018 million RMB, with a projected increase to 3,558 million RMB in 2024, and further growth to 4,500 million RMB in 2025 [7][10] - The company’s net profit for 2023 is 644 million RMB, expected to rise to 1,430 million RMB in 2024, and 1,896 million RMB in 2025 [7][10] - Earnings per share (EPS) is projected to grow from 1.43 RMB in 2023 to 4.21 RMB in 2025, with a corresponding price-to-earnings (PE) ratio of 21.4 in 2025 [7][10] Market Performance - The company has shown a market performance of -27% over the last 12 months, compared to the Shanghai Composite Index and the Chemical Pharmaceutical sector [4]